GH Research PLC (GHRS)
NASDAQ: GHRS · Real-Time Price · USD
9.95
-0.11 (-1.09%)
May 14, 2025, 10:00 AM - Market open
GH Research Employees
GH Research had 50 employees as of December 31, 2024. The number of employees increased by 1 or 2.04% compared to the previous year.
Employees
50
Change (1Y)
1
Growth (1Y)
2.04%
Revenue / Employee
n/a
Profits / Employee
-$842,140
Market Cap
617.18M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 50 | 1 | 2.04% |
| Dec 31, 2023 | 49 | 17 | 53.13% |
| Dec 31, 2022 | 32 | 18 | 128.57% |
| Dec 31, 2021 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GHRS News
- 6 days ago - GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - GH Research Reports Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - GH Research Announces Pricing of $150 Million Public Offering - GlobeNewsWire
- 3 months ago - GH Research Announces Proposed Public Offering - GlobeNewsWire
- 3 months ago - Why Is GH Research Stock Trading Higher On Monday? - Benzinga
- 3 months ago - GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction - GlobeNewsWire
- 3 months ago - GH Research to Provide Update on Phase 2b Trial with GH001 in TRD - GlobeNewsWire
- 4 months ago - GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents - GlobeNewsWire